We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Platelet Membrane Lipid Acts to Promote Blood Clotting

By Biotechdaily staff writers
Posted on 05 Aug 2002
A new study has revealed that the lipid phosphatidylserine (PS) plays a crucial role in the conversion of prothrombin to thrombin, which is the final step in the process of blood coagulation. More...
The study appeared in the June 3, 2002, online edition of the Journal of Biological Chemistry and in the August 2002 printed edition.

Factor Xa (FXa) binding to factor Va (FVa) on platelet-derived membranes containing surface-exposed phosphatidylserine (PS) forms the "prothrombinase complex” that is essential for efficient thrombin generation during blood coagulation. There are two naturally occurring isoforms of Fva: FVa1 and FVa2. These two isoforms differ by a three KDalton polysaccharide chain and have different coagulant activities.

A soluble form of PS (C6PS) was found to bind to FVa1 and FVa2 with comparable affinities and changes in FVa intrinsic fluorescence. At concentrations well below its critical micelle concentration, C6PS binding to bovine FVa2 enhanced its affinity for FXa in solution by nearly three orders of magnitude but had no effect on the affinity of FVa1 for FXa. This resulted in a soluble complex between FXa and FVa2, whose expected molecular weight was confirmed by calibrated native gel electrophoresis. This complex behaved as a normal Michaelis-Menten enzyme in its ability to produce thrombin from meizothrombin. The ability of soluble PS to trigger formation of a soluble prothrombinase complex suggested that exposure of PS molecules during platelet activation is likely the key event responsible for the assembly of an active membrane-bound complex.

Dr. Barry R. Lentz, professor of biochemistry and biophysics at the University of North Carolina School of Medicine (Chapel Hill, USA) and senior author, said that the findings unequivocally supported a new view, that PS can activate conversion of prothrombin to thrombin in the absence of the platelet membrane surface. It does so by triggering assembly of the enzyme complex, prothrombinase, which is crucial to that process.

Dr. Lentz added, "If you want to control blood coagulation--either to promote it or to diminish it in a setting where you do not want clots to form--the binding sites for phosphatidylserine may be good targets for drug design.”



Related Links:
University of North Carolina

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.